Research on Alzheimer's disease and neurodegenerative diseases is steadily progressing. In this section you will find various news items that make up the current news in this field, in Switzerland and around the world.
Lecanemab : results confirmed and approval for US market launch
Detailed results from the phase 3 clinical trial of lecanemab have been confirmed: although it does not stop the disease, the drug slows its progression. The Food and Drug Administration (FDA) has accepted the drug for marketing, following an accelerated application
Lecanemab effective against Alzheimer's disease - strong support for the toxic role of amyloid
The results of a global phase 3 clinical trial of lecanemab, a new treatment for Alzheimer's disease, have been published in a press release.
Dernière mise à jour : 11/08/2022